お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は多形性膠芽腫（GBM）の治療市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは多形性膠芽腫（GBM）の治療の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の多形性膠芽腫（GBM）の治療市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは多形性膠芽腫（GBM）の治療のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に多形性膠芽腫（GBM）の治療市場を分類しています。本研究に含まれる主な企業は：Merck、Teva Pharmaceutical、Arbor Pharmaceuticals、Sun Pharmaceutical、Roche

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Chemotherapy
    Radiotherapy
    Gene therapy
    Molecular biotechnology

用途別の市場セグメント：
    Hospital & Clinic
    ASCs
    Others

本レポートの詳細内容
世界の多形性膠芽腫（GBM）の治療市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、多形性膠芽腫（GBM）の治療タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の多形性膠芽腫（GBM）の治療収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の多形性膠芽腫（GBM）の治療市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、多形性膠芽腫（GBM）の治療市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

多形性膠芽腫（GBM）の治療のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：多形性膠芽腫（GBM）の治療のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：多形性膠芽腫（GBM）の治療の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章多形性膠芽腫（GBM）の治療企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：多形性膠芽腫（GBM）の治療の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：多形性膠芽腫（GBM）の治療の主要企業の概要を提供し、製品の説明と仕様、多形性膠芽腫（GBM）の治療の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Market Analysis and Insights: Global Glioblastoma Multiforme Treatment (GBM) Market
The global Glioblastoma Multiforme Treatment (GBM) market is projected to grow from US$ 602.4 million in 2024 to US$ 996.4 million by 2030, at a Compound Annual Growth Rate (CAGR) of 8.8% during the forecast period.
The US & Canada market for Glioblastoma Multiforme Treatment (GBM) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Glioblastoma Multiforme Treatment (GBM) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The Europe market for Glioblastoma Multiforme Treatment (GBM) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The global key companies of Glioblastoma Multiforme Treatment (GBM) include Merck, Teva Pharmaceutical, Arbor Pharmaceuticals, Sun Pharmaceutical and Roche, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Glioblastoma Multiforme Treatment (GBM) is widely used in various fields, such as Hospital & Clinic, ASCs and Others,, etc. Hospital & Clinic provides greatest supports to the Glioblastoma Multiforme Treatment (GBM) industry development. In 2023, global % revenue of Glioblastoma Multiforme Treatment (GBM) went into Hospital & Clinic filed and the proportion will reach to % in 2030. 
Report Covers:
This report presents an overview of global market for Glioblastoma Multiforme Treatment (GBM) market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Glioblastoma Multiforme Treatment (GBM), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Glioblastoma Multiforme Treatment (GBM), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Glioblastoma Multiforme Treatment (GBM) revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Glioblastoma Multiforme Treatment (GBM) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Glioblastoma Multiforme Treatment (GBM) revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Merck, Teva Pharmaceutical, Arbor Pharmaceuticals, Sun Pharmaceutical and Roche, etc.

Market Segmentation
By Company
    Merck
    Teva Pharmaceutical
    Arbor Pharmaceuticals
    Sun Pharmaceutical
    Roche

Segment by Type
    Chemotherapy
    Radiotherapy
    Gene therapy
    Molecular biotechnology

Segment by Application
    Hospital & Clinic
    ASCs
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Glioblastoma Multiforme Treatment (GBM) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glioblastoma Multiforme Treatment (GBM) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Glioblastoma Multiforme Treatment (GBM) revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Chemotherapy
    Table 3. Key Players of Radiotherapy
    Table 4. Key Players of Gene therapy
    Table 5. Key Players of Molecular biotechnology
    Table 6. Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 7. Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Glioblastoma Multiforme Treatment (GBM) Market Size by Region (2019-2024) & (US$ Million)
    Table 9. Global Glioblastoma Multiforme Treatment (GBM) Market Share by Region (2019-2024)
    Table 10. Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 11. Global Glioblastoma Multiforme Treatment (GBM) Market Share by Region (2025-2030)
    Table 12. Glioblastoma Multiforme Treatment (GBM) Market Trends
    Table 13. Glioblastoma Multiforme Treatment (GBM) Market Drivers
    Table 14. Glioblastoma Multiforme Treatment (GBM) Market Challenges
    Table 15. Glioblastoma Multiforme Treatment (GBM) Market Restraints
    Table 16. Global Glioblastoma Multiforme Treatment (GBM) Revenue by Players (2019-2024) & (US$ Million)
    Table 17. Global Glioblastoma Multiforme Treatment (GBM) Revenue Share by Players (2019-2024)
    Table 18. Global Top Glioblastoma Multiforme Treatment (GBM) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glioblastoma Multiforme Treatment (GBM) as of 2023)
    Table 19. Global Glioblastoma Multiforme Treatment (GBM) Industry Ranking 2022 VS 2023 VS 2024
    Table 20. Global 5 Largest Players Market Share by Glioblastoma Multiforme Treatment (GBM) Revenue (CR5 and HHI) & (2019-2024)
    Table 21. Global Key Players of Glioblastoma Multiforme Treatment (GBM), Headquarters and Area Served
    Table 22. Global Key Players of Glioblastoma Multiforme Treatment (GBM), Product and Application
    Table 23. Global Key Players of Glioblastoma Multiforme Treatment (GBM), Product and Application
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2019-2024) & (US$ Million)
    Table 26. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Type (2019-2024)
    Table 27. Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 28. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Type (2025-2030)
    Table 29. Global Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2019-2024) & (US$ Million)
    Table 30. Global Glioblastoma Multiforme Treatment (GBM) Revenue Share by Application (2019-2024)
    Table 31. Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 32. Global Glioblastoma Multiforme Treatment (GBM) Revenue Share by Application (2025-2030)
    Table 33. North America Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2019-2024) & (US$ Million)
    Table 34. North America Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2025-2030) & (US$ Million)
    Table 35. North America Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2019-2024) & (US$ Million)
    Table 36. North America Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2025-2030) & (US$ Million)
    Table 37. North America Glioblastoma Multiforme Treatment (GBM) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 38. North America Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2019-2024) & (US$ Million)
    Table 39. North America Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2025-2030) & (US$ Million)
    Table 40. Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2019-2024) & (US$ Million)
    Table 41. Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2025-2030) & (US$ Million)
    Table 42. Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2019-2024) & (US$ Million)
    Table 43. Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2025-2030) & (US$ Million)
    Table 44. Europe Glioblastoma Multiforme Treatment (GBM) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 45. Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2019-2024) & (US$ Million)
    Table 46. Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2025-2030) & (US$ Million)
    Table 47. China Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2019-2024) & (US$ Million)
    Table 48. China Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2025-2030) & (US$ Million)
    Table 49. China Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2019-2024) & (US$ Million)
    Table 50. China Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2025-2030) & (US$ Million)
    Table 51. Asia Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2019-2024) & (US$ Million)
    Table 52. Asia Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2025-2030) & (US$ Million)
    Table 53. Asia Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2019-2024) & (US$ Million)
    Table 54. Asia Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2025-2030) & (US$ Million)
    Table 55. Asia Glioblastoma Multiforme Treatment (GBM) Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 56. Asia Glioblastoma Multiforme Treatment (GBM) Market Size by Region (2019-2024) & (US$ Million)
    Table 57. Asia Glioblastoma Multiforme Treatment (GBM) Market Size by Region (2025-2030) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2019-2024) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2019-2024) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2025-2030) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Glioblastoma Multiforme Treatment (GBM) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 63. Middle East, Africa, and Latin America Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2019-2024) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2025-2030) & (US$ Million)
    Table 65. Merck Company Details
    Table 66. Merck Business Overview
    Table 67. Merck Glioblastoma Multiforme Treatment (GBM) Product
    Table 68. Merck Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024) & (US$ Million)
    Table 69. Merck Recent Developments
    Table 70. Teva Pharmaceutical Company Details
    Table 71. Teva Pharmaceutical Business Overview
    Table 72. Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Product
    Table 73. Teva Pharmaceutical Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024) & (US$ Million)
    Table 74. Teva Pharmaceutical Recent Developments
    Table 75. Arbor Pharmaceuticals Company Details
    Table 76. Arbor Pharmaceuticals Business Overview
    Table 77. Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Product
    Table 78. Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024) & (US$ Million)
    Table 79. Arbor Pharmaceuticals Recent Developments
    Table 80. Sun Pharmaceutical Company Details
    Table 81. Sun Pharmaceutical Business Overview
    Table 82. Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Product
    Table 83. Sun Pharmaceutical Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024) & (US$ Million)
    Table 84. Sun Pharmaceutical Recent Developments
    Table 85. Roche Company Details
    Table 86. Roche Business Overview
    Table 87. Roche Glioblastoma Multiforme Treatment (GBM) Product
    Table 88. Roche Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024) & (US$ Million)
    Table 89. Roche Recent Developments
    Table 90. Research Programs/Design for This Report
    Table 91. Key Data Information from Secondary Sources
    Table 92. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Glioblastoma Multiforme Treatment (GBM) Market Share by Type: 2023 VS 2030
    Figure 3. Chemotherapy Features
    Figure 4. Radiotherapy Features
    Figure 5. Gene therapy Features
    Figure 6. Molecular biotechnology Features
    Figure 7. Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 8. Global Glioblastoma Multiforme Treatment (GBM) Market Share by Application: 2023 VS 2030
    Figure 9. Hospital & Clinic Case Studies
    Figure 10. ASCs Case Studies
    Figure 11. Others Case Studies
    Figure 12. Glioblastoma Multiforme Treatment (GBM) Report Years Considered
    Figure 13. Global Glioblastoma Multiforme Treatment (GBM) Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 14. Global Glioblastoma Multiforme Treatment (GBM) Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 15. Global Glioblastoma Multiforme Treatment (GBM) Market Share by Region: 2023 VS 2030
    Figure 16. Global Glioblastoma Multiforme Treatment (GBM) Market Share by Players in 2023
    Figure 17. Global Top Glioblastoma Multiforme Treatment (GBM) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glioblastoma Multiforme Treatment (GBM) as of 2023)
    Figure 18. The Top 10 and 5 Players Market Share by Glioblastoma Multiforme Treatment (GBM) Revenue in 2023
    Figure 19. North America Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 20. North America Glioblastoma Multiforme Treatment (GBM) Market Share by Type (2019-2030)
    Figure 21. North America Glioblastoma Multiforme Treatment (GBM) Market Share by Application (2019-2030)
    Figure 22. North America Glioblastoma Multiforme Treatment (GBM) Market Share by Country (2019-2030)
    Figure 23. United States Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Canada Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Europe Glioblastoma Multiforme Treatment (GBM) Market Size YoY (2019-2030) & (US$ Million)
    Figure 26. Europe Glioblastoma Multiforme Treatment (GBM) Market Share by Type (2019-2030)
    Figure 27. Europe Glioblastoma Multiforme Treatment (GBM) Market Share by Application (2019-2030)
    Figure 28. Europe Glioblastoma Multiforme Treatment (GBM) Market Share by Country (2019-2030)
    Figure 29. Germany Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. France Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. U.K. Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Italy Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Russia Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Nordic Countries Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. China Glioblastoma Multiforme Treatment (GBM) Market Size YoY (2019-2030) & (US$ Million)
    Figure 36. China Glioblastoma Multiforme Treatment (GBM) Market Share by Type (2019-2030)
    Figure 37. China Glioblastoma Multiforme Treatment (GBM) Market Share by Application (2019-2030)
    Figure 38. Asia Glioblastoma Multiforme Treatment (GBM) Market Size YoY (2019-2030) & (US$ Million)
    Figure 39. Asia Glioblastoma Multiforme Treatment (GBM) Market Share by Type (2019-2030)
    Figure 40. Asia Glioblastoma Multiforme Treatment (GBM) Market Share by Application (2019-2030)
    Figure 41. Asia Glioblastoma Multiforme Treatment (GBM) Market Share by Region (2019-2030)
    Figure 42. Japan Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. South Korea Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. China Taiwan Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Southeast Asia Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. India Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Australia Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Glioblastoma Multiforme Treatment (GBM) Market Size YoY (2019-2030) & (US$ Million)
    Figure 49. Middle East, Africa, and Latin America Glioblastoma Multiforme Treatment (GBM) Market Share by Type (2019-2030)
    Figure 50. Middle East, Africa, and Latin America Glioblastoma Multiforme Treatment (GBM) Market Share by Application (2019-2030)
    Figure 51. Middle East, Africa, and Latin America Glioblastoma Multiforme Treatment (GBM) Market Share by Country (2019-2030)
    Figure 52. Brazil Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Mexico Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Turkey Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Saudi Arabia Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Israel Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. GCC Countries Glioblastoma Multiforme Treatment (GBM) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. Merck Revenue Growth Rate in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024)
    Figure 59. Teva Pharmaceutical Revenue Growth Rate in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024)
    Figure 60. Arbor Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024)
    Figure 61. Sun Pharmaceutical Revenue Growth Rate in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024)
    Figure 62. Roche Revenue Growth Rate in Glioblastoma Multiforme Treatment (GBM) Business (2019-2024)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed